MedTrace Logo

Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%

NCT01607671 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-05-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility of rapid evaluation and administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior ischemic optic neuropathy. Secondary goals are to evaluate if such treatment reduces the progression or improves recovery of patients who are randomly assigned to treatment versus standard of care.

Conditions

  • Optic Neuropathy, Ischemic
  • Anterior Ischemic Optic Neuropathy
  • Ischemic Optic Neuropathy
  • Optic Neuropathy, Anterior Ischemic

Interventions

DRUG

Timolol maleate

Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.

Sponsors & Collaborators

  • Fraser Health

    lead OTHER

Principal Investigators

  • Martin A SuttonBrown, MD · Fraser Health Region

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01607671 on ClinicalTrials.gov